CVMA | News & Events | ENOVAT and WSAVA Join Forces on Clinical Guidelines for Antimicrobial Treatment
CVMA-ACMV

News, Events & COVID-19 RESOURCES

ENOVAT and WSAVA Join Forces on Clinical Guidelines for Antimicrobial Treatment

September 10, 2021

Partnership will tackle lack of resources on veterinary antimicrobial treatmentChair, WSAVA Therapeutics Guidelines Group, Dr. Luca Guardabassi

 
The European Network for Optimization of Veterinary Antimicrobial Treatment (ENOVAT) and the World Small Animal Veterinary Association (WSAVA) have joined forces to develop and disseminate evidence-based clinical guidelines for the optimization of antimicrobial treatment in companion animal veterinary medicine.
 
ENOVAT works to optimize veterinary antimicrobial use with a special emphasis on the development of antimicrobial treatment Guidelines and the refinement of microbiological diagnostic procedures. ENOVAT, which is funded by the European Cooperation in Science and Technology (COST), is currently working with the European Society of Clinical Microbiology and Infectious Diseases’ (ESCMID) Study Group of Veterinary Microbiology (ESGVM) on two sets of Guidelines:Chair, ENOVAT Guidelines initiative, Dr. Lisbeth Rem Jessen
 
  • A set of Guidelines for Canine acute diarrhea
  • A set of Guidelines for antimicrobial use in surgical prophylaxis in companion animals. 
Under the terms of the partnership, the WSAVA will provide feedback from its 115 association members to inform the content of the Guidelines and ensure their relevance globally. The association will also support the translation of the Guidelines into a range of languages and produce a series of engaging, easily-understood infographics to help reinforce key information points. Two members of the WSAVA Therapeutics Guidelines Group, its Chair Dr Luca Guardabassi and Dr Scott Weese, are contributing to their development. 
 
The WSAVA’s Therapeutics Guidelines Group is a team of global experts focused on ensuring best practices for the selection and responsible use of medicines in companion animals, while engaging the participation of stakeholders and the WSAVA global community in the concept of One Health. Its work is kindly supported by Zoetis.
 
Commenting on the WSAVA’s support for the new Guidelines, Dr Guardabassi said: “This is a very timely collaboration as it is essential to offer veterinarians evidence-based guidelines on rational antimicrobial use in companion animals.
“The WSAVA looks forward to playing a key role in disseminating the key recommendations from these documents, making them accessible and understandable to a wide audience of general practitioners on a global scale”. 
 
From ENOVAT, the Chair of the Guidelines initiative, Dr Lisbeth Rem Jessen, said: “The goal of the ENOVAT Guidelines is to advance antimicrobial stewardship while providing best possible care for our patients in veterinary practice.” She also emphasized the crucial role of practicing veterinarians to the success of the Guidelines and the importance of the WSAVA collaboration in bridging the gap to end-users. 
 
Note to editors:
The WSAVA represents more than 200,000 veterinarians worldwide through its 115 member associations and works to enhance standards of clinical care for companion animals. Its core activities include the development of WSAVA Global Guidelines in key areas of veterinary practice, including nutrition, pain management and vaccination, together with lobbying on important issues affecting companion animal care worldwide.
ENOVAT is a COST Action network of more than 240 stakeholders from 34 countries in Europe and 9 other countries. The stakeholders comprise microbiologists, clinicians, pharmacologists, communication specialists and other experts that have joined forces to optimize antimicrobial use in animals through refinement of microbiological diagnostics and by developing antimicrobial treatment guidelines.
 
For further information:
Rebecca George, George PR
Tel: 01449 737281/07974 161108/
email: rebecca@georgepr.com